<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Holmberg CJ</submitter><funding>Wallenberg Centre for Molecular and Translational Medicine</funding><funding>Knut and Alice Wallenberg Foundation</funding><funding>University of Gothenburg, Sweden</funding><pagination>472</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9856283</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(2)</volume><pubmed_abstract>Isolated limb perfusion (ILP) is an effective locoregional treatment for melanoma in-transit metastasis, but the advent of modern effective immunotherapy, such as ICI (immune checkpoint inhibitors), has changed the treatment landscape. The primary aims of this study were to compare the characteristics of the patient population receiving ILP before and after the introduction of modern systemic treatments and to assess if outcomes after ILP were influenced by previous immunotherapy treatment. A single-centre analysis of patients that underwent ILP for melanoma in-transit metastasis between 2010 and 2021 was conducted, with patients grouped and compared by treatment time period: pre-ICI era (2010-2014) and ICI era (2017-2021). 218 patients were included. Patients undergoing ILP in the ICI era</pubmed_abstract><journal>Cancers</journal><pubmed_title>Effects of the Introduction of Modern Immunotherapy on the Outcome of Isolated Limb Perfusion for Melanoma In-Transit Metastases.</pubmed_title><pmcid>PMC9856283</pmcid><funding_grant_id>01</funding_grant_id><pubmed_authors>Olofsson Bagge R</pubmed_authors><pubmed_authors>Mattsson J</pubmed_authors><pubmed_authors>Holmberg CJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effects of the Introduction of Modern Immunotherapy on the Outcome of Isolated Limb Perfusion for Melanoma In-Transit Metastases.</name><description>Isolated limb perfusion (ILP) is an effective locoregional treatment for melanoma in-transit metastasis, but the advent of modern effective immunotherapy, such as ICI (immune checkpoint inhibitors), has changed the treatment landscape. The primary aims of this study were to compare the characteristics of the patient population receiving ILP before and after the introduction of modern systemic treatments and to assess if outcomes after ILP were influenced by previous immunotherapy treatment. A single-centre analysis of patients that underwent ILP for melanoma in-transit metastasis between 2010 and 2021 was conducted, with patients grouped and compared by treatment time period: pre-ICI era (2010-2014) and ICI era (2017-2021). 218 patients were included. Patients undergoing ILP in the ICI era</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-04T10:19:59.632Z</modification><creation>2025-02-19T00:12:45.757Z</creation></dates><accession>S-EPMC9856283</accession><cross_references><pubmed>36672422</pubmed><doi>10.3390/cancers15020472</doi></cross_references></HashMap>